• Home
  • » 
  • Reports
  • » 
  • Non-Viral / Intracellular Drug Delivery ...

Intracellular Drug Delivery

Non-Viral / Intracellular Drug Delivery Systems Market by Type of Molecule (Small Molecules and Biologics), Type of Biologics delivered (RNAi / mRNA, DNA / Oligonucleotides, Antibodies, Proteins / Peptides), Type of Vehicle Used (Cell Penetrating Peptides, Extracellular Vesicles, Oligonucleotides, Nanoparticles and Polymers), Type of Therapeutic Area (Infectious Diseases, Oncological Disorders, Genetic Disorders, Neurological Disorders, Hepatic Disorders, Cardiovascular Disorders and Other Disorders), Type of Payments (Upfront Payments and Milestone Payments) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts (2nd Edition), 2023-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2023

  • Pages
    235

  • View Count
    11061

  • Buy Now

Example Insights

Non-Viral-Drug-Delivery-Systems-Context-thumb Non-Viral-Drug-Delivery-Systems-Providers-thumb Non-Viral-Drug-Delivery-Systems-Technologies-thumb Non-Viral-Drug-Delivery-Systems-benchmarks-thumb
Non-Viral-Drug-Delivery-Systems-Collaborations-thumb Non-Viral-Drug-Delivery-Systems-stakeholders-thumb Non-Viral-Drug-Delivery-Systems-Framework-thumb Non-Viral-Drug-Delivery-Systems-delivery-thumb
Non-Viral-Drug-Delivery-Systems-Scenarios-thumb Non-Viral-Drug-Delivery-Systems-regions-thumb    

Report Description

In recent years, efficient methods for facilitation of intracellular drug delivery have become a prominent need within the modern biopharmaceutical industry.  Targeting the delivery of a pharmacological substance to its intended physiological site of action ensures that adequate concentration of the therapeutics is made available, in order to elicit the desired clinical benefits and limit off-target / systemic toxicity.  In fact, a study suggests that over 20% of the proteome, including oncogenic proteins, cell metabolism regulators, components of different signal transduction pathways and enzymes, is localized within the cell membrane. Further, considering the fact that only 10% of the human genome can selectively bind to small molecule pharmaceuticals, industry experts believe that intracellular biologics, particularly nucleic acid-based therapeutic interventions, present a promising alternative to conventional therapies.  Furthermore, recent advancements in cell biology and intracellular delivery systems have led to the identification of several potential therapeutic targets for a variety of clinical disorders. These targets have been demonstrated to be capable of aiding the treatment of disease indications which were previously considered incurable, as they were localized within the confines of the cell membrane. It is also worth highlighting that majority of the available biopharmaceutical interventions, such as gene therapies, require cell membrane permeabilization in order to mediate their therapeutic effects. 

Gene delivery systems are usually based on viral and non-viral vectors and known to enable the entry of pharmacologically active compounds into the matrix of the cytoplasm.  Specifically, viral drug delivery systems utilize the ability of viruses to inject their DNA inside host cells. However, such systems are often fraught with several challenges, such as immunogenicity, toxicity and reverse mutation. In order to overcome the aforementioned challenges and enable the delivery of intracellular biologics, researchers have developed various non-viral delivery systems, including exosome-based drug delivery techniques, cell-penetrating peptides (CPP) and nanoparticle-based processes. Further, numerous technology developers have signed several strategic agreements with therapy developers in order to facilitate the development of drug formulations that can be delivered to the intracellular matrix. Additionally, close to 1,300 patents related to such technologies have been filed / granted in the past few years, demonstrating the continued innovation being carried out in this domain. At present, more than 20,000 oligonucleotide-based therapeutics focused studies are being conducted across the globe.  In this context, it is also worth mentioning that, recently, Novartis received the USFDA approval for Leqvio (inclisiran), a first-in-class siRNA therapy for lower LDL cholesterol, which is delivered using an intracellular drug delivery technology.  Other examples of recently approved gene therapies that are being delivered intracellularly include (alphabetical order) ABECMA (idecabtagene vicleucel; manufactured by Celgene), BREYANZI (lisocabtagene maraleucel; manufactured by Juno Therapeutics) and KYMRIAH (tisagenlecleucel; manufactured by Novartis).  Driven by a growing demand for systems that can  efficiently deliver therapeutic interventions in intracellular spaces, the non-viral drug delivery systems market is likely to witness significant growth in the short to mid-term. 

Scope of the Report

The Non-Viral Drug Delivery Systems Market (2nd Edition), 2023-2035: Distribution by Type of Molecule Delivered (Small Molecules and Biologics), Type of Biologic Delivered (Antibodies, DNA, RNA, Proteins / Peptides), Type of Technology (Cell Penetrating Peptides, Extracellular Vesicles, Oligonucleotides, Nanoparticles and Polymers), Target Therapeutic Area (Infectious Diseases, Oncological Disorders, Genetic Disorders, Neurological Disorders, Hepatic Disorders, Cardiovascular Disorders and Other Disorders), Type of Payment (Upfront Payments and Milestone Payments) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts report features an extensive study of the current landscape and the likely future opportunities of players engaged in offering intracellular drug delivery technologies in the healthcare domain, over next 12 years. Amongst other elements, the report includes:

  • An executive summary of the key insights captured during our research, offering a high-level view on the current state of the non-viral drug delivery systems market and its likely evolution in the short to mid and long term.
  • A brief introduction to important concepts related to non-viral intracellular drug delivery, featuring information on various types of non-viral drug delivery systems and their primary applications in the healthcare domain, along with details related to the recent advancements that have been reported in this market space.
  • A detailed review of the overall market landscape of non-viral drug delivery systems, featuring an in-depth analysis based on several relevant parameters, such as therapeutic portfolio, type of molecule delivered (small molecules and biologics), type of biologic delivered (antibodies, DNA, RNA and proteins / peptides), type of interaction (co-administration, conjugation, encapsulation and others) and Type of Technology (cell penetrating peptides, extracellular vesicles, oligonucleotides, nanoparticles, polymers). In addition, it features a list of technology developers and a detailed analysis based on their year of establishment, company size, type of company and geographical location.
  • An in-depth analysis, highlighting the contemporary market trends, using four schematic representations, including a waffle chart representation, (highlighting the distribution of various types of vehicles used for delivering payloads), a heat map representation (based on company size and type of molecule delivered), a vertical stacked column bar chart representation (location of headquarters and type of service provider), a vertical column clustered chart representation (based on company size and location of headquarters).
  • An insightful company competitiveness analysis of non-viral drug delivery systems providers, taking into consideration various relevant parameters, such as years of experience and product portfolio (in terms of number of technologies offered, type of biologics delivered and type of linkage) and partnership strength (in terms of number of partnerships, partnership year, partnerships based on geographies, type of partnerships, therapeutic area, payment portfolio and type of biologics delivered).
  • Elaborate profiles of prominent players engaged in offering non-viral drug delivery technologies, across North America, Europe and Asia. Each company profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters and key members of the executive team), details on its technology portfolio and recent developments and an informed future outlook. 
  • An in-depth analysis of the various patents that have been filed / granted patent related to intracellular drug delivery technologies, based on various parameters, such as type of patent, publication year, application year, granted patents, filed patents, issuing authority, type of player, CPC symbols (in terms of the size of intellectual property portfolio), leading industry / non-industry players and inventors (in terms of number of patents filed / granted). Further it features a patent benchmarking analysis and a detailed patent valuation analysis.
  • An insightful analysis of various partnerships inked between stakeholders engaged within the non-viral drug delivery domain, based on several relevant parameters, such as year of partnership, type of partner (industry and non-industry), purpose of partnership (research and development, research, development and commercialization, product development, product development and commercialization, product development and manufacturing, product development and manufacturing, commercialization, manufacturing, acquisition / merger and others), type of partnership (technology licensing agreements, technology evaluation agreements, technology integration agreements, technology utilization agreements, acquisitions / mergers and others), therapeutic area (oncological disorders, infectious diseases, genetic disorders, hepatic disorders, neurological disorders, cardiovascular disorders, ophthalmic diseases, pulmonary diseases, metabolic disorders, immunological disorders and others), type of payment model (upfront payments, milestone payments, royalties and others), type of molecule delivered (small molecules, biologics),  type of biologic delivered (antibodies, RNA, DNA and proteins / peptides), most active players (in terms of number of deals inked), most popular technologies (in terms of number of deals inked for technologies) and regional distribution of partnership activity that have been undertaken in this domain, during the period 2015-2022.
  • An insightful framework which provides four zones of evaluation and product portfolio matrix based on various parameters, such as number of drugs in the pipeline, number of companies, deal amount, partnership activity, trends highlighted in number of grants, number of publications, google hits and qualitative scoring. It also provides a Kalbach, competitive assessment framework and BCG matrix for respective non-viral drug delivery technologies currently employed by stakeholders.

One of the key objectives of this report was to estimate the existing market opportunity and the future growth potential of the non-viral drug delivery market over the coming years. We have provided an informed estimate on the likely financial evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and upcoming opportunity segmented across important parameters, such as type of molecule delivered (small molecules and biologics), type of biologic delivered (antibodies, RNA, DNA and proteins / peptides), type of technology (Cell Penetrating Peptides, Extracellular Vesicles, Oligonucleotides, Nanoparticles and Polymers), target therapeutic area (infectious diseases, oncological disorders, genetic disorders, neurological disorders, hepatic disorders, cardiovascular disorders and other disorders), type of payment model (upfront payments and milestone payments) and key geographical regions (North America, Europe, Asia, Latin America, Middle East and North Africa and rest of the world).

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

  • Who are the leading players engaged in the development of intracellular drug delivery technologies?
  • Which partnership models are commonly adopted by stakeholders engaged in this domain?
  • What type of molecule can be delivered using intracellular drug delivery technologies?
  • How is the intellectual property landscape related to intracellular drug delivery likely to evolve in the foreseen future?
  • How is the current and future market opportunity likely to be distributed across key market segments and geographical region?

Contents

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Market Segmentations
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Need for Targeted Drug Delivery
3.3. Advanced Approaches for Delivery of Drug Payloads
3.3.1. Nanoparticle Delivery Systems
3.3.1.1. Liposomes
3.3.1.2. Nanoparticles / Microparticles
3.3.1.3. PEGylation
3.3.1.4. Cell Penetrating Peptides (CPPs)
3.3.2. Other Drug Delivery Technologies
3.4. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Intracellular Drug Delivery: List of Technologies
4.2.1. Analysis by Type of Molecule Delivered 
4.2.2. Analysis by Type of Biologic Delivered
4.2.3. Analysis by Type of Interaction
4.2.4. Analysis by Therapeutic Portfolio
4.3. Intracellular Drug Delivery: List of Technology Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Type of Company
4.3.4. Analysis by Location of Headquarters (By Region)

5. KEY INSIGHTS
5.1. Chapter Overview
5.2. Analysis by Type of Technology
5.3. Analysis by Company Size and Type of Molecule Delivered
5.4. Analysis by Location of Headquarters (Region-wise) and Type of Service Provider
5.5. Analysis by Company Size and Location of Headquarters

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions / Key Parameters
6.3. Methodology
6.4. Company Competitiveness Analysis: Benchmarking of Portfolio Strength
6.5. Company Competitiveness Analysis: Benchmarking of Partnership Strength
6.5.1. Company Competitiveness Analysis: Very Small Companies
6.5.2. Company Competitiveness Analysis: Small Companies
6.5.3. Company Competitiveness Analysis: Mid-Sized Companies
6.5.4. Company Competitiveness Analysis: Large and Very Large Companies

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Arcturus Therapeutics
7.2.1. Company Overview
7.2.2. Technology Portfolio
7.2.3. Recent Developments and Future Outlook

7.3. Bio-Path
7.3.1. Company Overview
7.3.2. Technology Portfolio
7.3.3. Recent Developments and Future Outlook

7.4. CureVac
7.4.1. Company Overview
7.4.2. Technology Portfolio
7.4.3. Recent Developments and Future Outlook

7.5. Entos Pharmaceuticals
7.5.1. Company Overview
7.5.2. Technology Portfolio
7.5.3. Recent Developments and Future Outlook

7.6. eTheRNA immunotherapies
7.6.1. Company Overview
7.6.2. Technology Portfolio
7.6.3. Recent Developments and Future Outlook

7.7. Matinas BioPharma
7.7.1. Company Overview
7.7.2. Technology Portfolio
7.7.3. Recent Developments and Future Outlook

7.8. MDimune
7.8.1. Company Overview
7.8.2. Technology Portfolio
7.8.3. Recent Developments and Future Outlook

7.9. PCI Biotech
7.9.1. Company Overview
7.9.2. Technology Portfolio
7.9.3. Recent Developments and Future Outlook

8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Intracellular Drug Delivery Technologies: Patent Analysis
8.3.1. Analysis by Type of Patent
8.3.2. Analysis by Publication Year
8.3.3. Analysis by Application Year
8.3.4. Analysis by Cumulative Number of Granted Patents
8.3.5. Analysis by Cumulative Number of Patent Applications
8.3.6. Analysis by Issuing Authority
8.3.7. Analysis by Type of Player
8.3.8. Leading Players: Analysis by Number of Patents
8.3.9. Leading Inventors: Analysis by Number of Patents
8.3.10. Analysis by Top Sections
8.3.11. Intracellular Drug Delivery Technologies: Patent Benchmarking Analysis
8.4. Intracellular Drug Delivery Technologies: Patent Valuation Analysis

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Intracellular Drug Delivery Technologies: List of Partnerships and Collaborations
9.3.1. Cumulative Analysis of Partnerships by Year, 2015-2022
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership, 2015-2022
9.3.4. Analysis by Purpose of Partnership
9.3.5. Analysis by Type of Molecule Delivered
9.3.6. Analysis by Type of Biologic Delivered
9.3.7. Analysis by Target Therapeutic Area
9.3.8 Analysis by Year of Partnership and Type of Payment Model Employed, 2015-2022
9.3.9. Analysis by Year of Partnership and Type of Company, 2015-2022
9.3.10. Analysis by Purpose of Partnership and Type of Company
9.3.11. Most Active Players: Analysis by Number of Partnerships
9.3.12. Most Popular Technologies: Analysis by Number of Partnerships
9.3.13. Analysis by Region
9.3.14. Local and International Agreements
9.3.15. Intracontinental and Intercontinental Agreements

10. OPPORTUNITY ASSESSMENT FRAMEWORK: KALBACH INNOVATION MODEL, COMPETITVE ASSESSMENT FRAMEWORK AND BCG MATRIX
10.1. Chapter Overview
10.2. Kalbach Innovation Model
10.2.1. Key Assumptions and Methodology
10.2.2. Analysis by Trends in Research Activity
10.2.3. Analysis by Trends in Investment Activity
10.2.4. Analysis by Trends in Partnership Activity
10.2.5. Analysis by Number of Technologies
10.2.6. Analysis by Trends in Deal Amount
10.2.7. Analysis by Number of Google Hits
10.2.8. Qualitative and Quantitative Assessment based on Secondary and Primary Research
10.2.9. Kalbach Innovation Model: Output Analysis

10.3. Competitive Assessment Framework
10.3.1. Key Assumptions and Methodology
10.3.2. Competitive Assessment Framework: Output Analysis

10.4. BCG Matrix
10.4.1. Key Assumptions and Methodology
10.4.2. BCG Matrix: Output Analysis

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions
11.3. Forecast Methodology
11.4. Global Non-Viral Intracellular Drug Delivery Technologies Market, 2022-2035
11.5. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Payment Model Employed, 2022 and 2035
11.5.1 Non-Viral Intracellular Drug Delivery Technologies Market for Milestone Payments, 2022-2035
11.5.2 Non-Viral Intracellular Drug Delivery Technologies Market for Upfront Payments, 2022-2035
11.6. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Molecule Delivered, 2022 and 2035
11.6.1 Non-Viral Intracellular Drug Delivery Technologies Market for Biologics, 2022-2035
11.6.2 Non-Viral Intracellular Drug Delivery Technologies Market for Small Molecules, 2022-2035
11.7. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Biologic Delivered, 2022 and 2035
11.7.1 Non-Viral Intracellular Drug Delivery Technologies Market for RNA, 2022-2035
11.7.2 Non-Viral Intracellular Drug Delivery Technologies Market for DNA, 2022-2035
11.7.3 Non-Viral Intracellular Drug Delivery Technologies Market for Proteins / Peptides, 2022-2035
11.7.4 Non-Viral Intracellular Drug Delivery Technologies Market for Antibodies, 2022-2035
11.8. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Technology, 2022 and 2035
11.8.1. Non-Viral Intracellular Drug Delivery Technologies Market for Nanoparticles, 2022-2035
11.8.2 Non-Viral Intracellular Drug Delivery Technologies Market for Extracellular Vesicles, 2022-2035
11.8.3 Non-Viral Intracellular Drug Delivery Technologies Market for Polymers, 2022-2035
11.8.4 Non-Viral Intracellular Drug Delivery Technologies Market for Oligonucleotides, 2022-2035
11.8.5 Non-Viral Intracellular Drug Delivery Technologies Market for Cell Penetrating Peptides, 2022-2035
11.9. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Target Therapeutic Areas, 2022 and 2035
11.9.1 Non-Viral Intracellular Drug Delivery Technologies Market for Infectious Diseases, 2022-2035
11.9.2 Non-Viral Intracellular Drug Delivery Technologies Market for Oncological Disorders, 2022-2035
11.9.3 Non-Viral Intracellular Drug Delivery Technologies Market for Genetic Disorders, 2022-2035
11.9.4 Non-Viral Intracellular Drug Delivery Technologies Market for Cardiovascular Disorders 2022-2035
11.9.5 Non-Viral Intracellular Drug Delivery Technologies Market for Hepatic Disorders, 2022-2035
11.9.6 Non-Viral Intracellular Drug Delivery Technologies Market for Neurological Disorders, 2022-2035
11.9.7 Non-Viral Intracellular Drug Delivery Technologies Market for Other Diseases, 2022-2035
11.10. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Geography, 2022 and 2035
11.10.1. Non-Viral Intracellular Drug Delivery Technologies Market in North America, 2022-2035
11.10.2. Non-Viral Intracellular Drug Delivery Technologies Market in Europe, 2022-2035
11.10.3. Non-Viral Intracellular Drug Delivery Technologies Market in Asia, 2022-2035
11.10.4. Non-Viral Intracellular Drug Delivery Technologies Market in Rest of the World, 2022-2035
11.10.5. Non-Viral Intracellular Drug Delivery Technologies Market in Middle East and North Africa, 2022-2035
11.10.6. Non-Viral Intracellular Drug Delivery Technologies Market in Latin America, 2022-2035

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Biond Biologics
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Tehila BenMoshe, Chief Executive Officer and Itay Friedman, Vice President Clinical Development

13.3. Carmine Therapeutics
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Don Haut, Chief Executive Officer

13.4. Eyevensys
13.4.1. Company Snapshot
13.4.2. Interview Transcript: Thierry Bordet, Chief Scientific Officer

13.5. Generation Bio
13.5.1. Company Snapshot
13.5.2. Interview Transcript: Maren Killackey, Senior Director, Investor Relations and Communications

13.6. PCI Biotech
13.6.1. Company Snapshot
13.6.2. Interview Transcript: Anders Høgset, Research Director / Chief Scientific Officer

13.7. SRI International
13.7.1. Company Snapshot
13.7.2. Interview Transcript: Melissa Wagner, Strategic Business Executive, Biosciences Division

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Mechanisms of Drug Transport Through Intestinal Epithelium
Figure 4.1 Non-Viral Intracellular Drug Delivery Technologies: Distribution by Type of Molecule Delivered
Figure 4.2 Non-Viral Intracellular Drug Delivery Technologies: Distribution by Type of Biologic Delivered
Figure 4.3 Non-Viral Intracellular Drug Delivery Technologies: Distribution by Type of Interaction
Figure 4.4 Non-Viral Intracellular Drug Delivery Technology Providers: Most Active Player Based on Therapeutic Portfolio
Figure 4.5 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Year of Establishment
Figure 4.6 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Company Size
Figure 4.7 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Type of Company
Figure 4.8 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Location of Headquarters (By Region)
Figure 5.1 Key Insights: Distribution by Type of Technology (Waffle Chart Representation)
Figure 5.2 Key Insights: Distribution by Company Size and Type of Molecule Delivered (Heat Map Representation)
Figure 5.3 Key Insights: Distribution by Location of Headquarters (Region-wise) and Type of Service Provider (Vertical Stacked Column Chart)
Figure 5.4 Key Insights: Distribution by Company Size and Location of Headquarters (Vertical Clustered Column Chart)
Figure 6.1 Company Competitiveness Analysis: Benchmarking of Product Portfolio
Figure 6.2 Company Competitiveness Analysis: Benchmarking of Partnership Strength
Figure 6.3 Company Competitiveness Analysis: Very Small Companies
Figure 6.4 Company Competitiveness Analysis: Small Companies
Figure 6.5 Company Competitiveness Analysis: Mid-sized Companies
Figure 6.6 Company Competitiveness Analysis: Large and Very Large Companies
Figure 8.1 Intracellular Drug Delivery Technologies: Patent Analysis
Figure 8.2 Patent Analysis: Distribution by Type of Patent
Figure 8.3 Patent Analysis: Distribution by Publication Year
Figure 8.4 Patent Analysis: Distribution by Application Year
Figure 8.5 Patent Analysis: Distribution by Cumulative Number of Granted Patents
Figure 8.6 Patent Analysis: Distribution by Cumulative Number of Patent Applications
Figure 8.7 Patent Analysis: Distribution by Issuing Authority
Figure 8.8 Patent Analysis: Distribution by Type of Player
Figure 8.9 Leading Players: Distribution by Number of Patents
Figure 8.10 Leading Inventors: Distribution by Number of Patents
Figure 8.11 Patent Analysis: Distribution by Top Sections
Figure 8.12 Intracellular Drug Delivery Technologies: Patent Benchmarking Analysis
Figure 8.13 Intracellular Drug Delivery Technologies: Patent Valuation Analysis
Figure 8.18 Patent Analysis: Leading Patents: Analysis by Number of Citations
Figure 9.1 Partnerships and Collaborations: Cumulative Distribution of Partnerships by Year, 2015-2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2022
Figure 9.4 Partnerships and Collaborations: Distribution by Purpose of Partnership
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Molecule Delivered
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Biologic Delivered
Figure 9.7 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Figure 9.8 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner 2015-2022
Figure 9.9 Partnerships and Collaborations: Purpose of Partnership and Type of Company
Figure 9.10 Most Active Players: Distribution by Number of Partnerships
Figure 9.11 Most Popular Technologies: Distribution by Number of Partnerships
Figure 9.12 Partnerships and Collaborations: Distribution by Region
Figure 9.13 Partnerships and Collaborations: Distribution by Year of Partnership, Type of Payment Model Employed and Amount Raised (USD Million)
Figure 9.14 Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 9.15 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
Figure 10.1 Opportunity Assessment Framework: Trends in Research Activity
Figure 10.2 Opportunity Assessment Framework: Trend in Investment Activity
Figure 10.3 Opportunity Assessment Framework: Trends in Partnership Activity
Figure 10.4 Opportunity Assessment Framework: Analysis by Number of Technologies
Figure 10.5 Opportunity Assessment Framework: Analysis by Trends in Deal Amount
Figure 10.6 Opportunity Assessment Framework: Analysis by Number of Google Hits
Figure 10.7 Opportunity Assessment Framework: Spider Web Representation
Figure 10.8 Opportunity Assessment Framework: Kalbach Innovation Model
Figure 10.9 Opportunity Assessment Framework: Competitive Assessment Framework
Figure 10.10 Opportunity Assessment Framework: BCG Matrix
Figure 11.1 Global Non-Viral Intracellular Drug Delivery Technologies Market, 2022-2035
Figure 11.2 Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Payment Model Employed, 2022 and 2035
Figure 11.3 Non-Viral Intracellular Drug Delivery Technologies Market for Milestone Payments, 2022-2035
Figure 11.4 Non-Viral Intracellular Drug Delivery Technologies Market for Upfront Payments, 2022-2035
Figure 11.5 Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Molecule Delivered, 2022 and 2035
Figure 11.6 Non-Viral Intracellular Drug Delivery Technologies Market for Biologics, 2022-2035
Figure 11.7 Non-Viral Intracellular Drug Delivery Technologies Market for Small Molecules, 2022-2035
Figure 11.8 Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Biologic Delivered, 2022 and 2035
Figure 11.9 Non-Viral Intracellular Drug Delivery Technologies Market for RNA, 2022-2035
Figure 11.10 Non-Viral Intracellular Drug Delivery Technologies Market for DNA, 2022-2035
Figure 11.11 Non-Viral Intracellular Drug Delivery Technologies Market for Proteins / Peptides, 2022-2035
Figure 11.12 Non-Viral Intracellular Drug Delivery Technologies Market for Antibodies, 2022-2035
Figure 11.13 Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Technology, 2022 and 2035
Figure 11.14 Non-Viral Intracellular Drug Delivery Technologies Market for Nanoparticles, 2022-2035
Figure 11.15 Non-Viral Intracellular Drug Delivery Technologies Market for Extracellular Vesicles, 2022-2035
Figure 11.16 Non-Viral Intracellular Drug Delivery Technologies Market for Polymers, 2022-2035
Figure 11.17 Non-Viral Intracellular Drug Delivery Technologies Market for Oligonucleotides, 2022-2035
Figure 11.18 Non-Viral Intracellular Drug Delivery Technologies Market for Cell Penetrating Peptides, 2022-2035
Figure 11.19 Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Target Therapeutic Areas, 2022 and 2035
Figure 11.20 Non-Viral Intracellular Drug Delivery Technologies Market for Infectious Diseases, 2022-2035
Figure 11.21 Non-Viral Intracellular Drug Delivery Technologies Market for Oncological Disorders, 2022-2035
Figure 11.22 Non-Viral Intracellular Drug Delivery Technologies Market for Genetic Disorders, 2022-2035
Figure 11.23 Non-Viral Intracellular Drug Delivery Technologies Market for Cardiovascular Disorders 2022-2035
Figure 11.24 Non-Viral Intracellular Drug Delivery Technologies Market for Hepatic Disorders, 2022-2035
Figure 11.25 Non-Viral Intracellular Drug Delivery Technologies Market for Neurological Disorders, 2022-2035
Figure 11.26 Non-Viral Intracellular Drug Delivery Technologies Market for Other Diseases, 2022-2035
Figure 11.27 Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Geography, 2022 and 2035
Figure 11.28 Non-Viral Intracellular Drug Delivery Technologies Market in North America, 2022-2035
Figure 11.29 Non-Viral Intracellular Drug Delivery Technologies Market in Europe, 2022-2035
Figure 11.30 Non-Viral Intracellular Drug Delivery Technologies Market in Asia, 2022-2035
Figure 11.31 Non-Viral Intracellular Drug Delivery Technologies Market in Rest of the World, 2022-2035
Figure 11.32 Non-Viral Intracellular Drug Delivery Technologies Market in Middle East and North Africa, 2022-2035
Figure 11.33 Non-Viral Intracellular Drug Delivery Technologies Market in Latin America, 2022-2035

List Of Tables

Table 4.1 List of Non-Viral Intracellular Drug Delivery Technologies
Table 4.2 Non-Viral Intracellular Drug Delivery Technologies: Information on Type of Biologic Delivered
Table 4.3 List of Non-Viral Intracellular Drug Delivery Technology Developers
Table 6.1 Company Competitiveness Analysis: Benchmarking of Product Portfolio
Table 6.2 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Table 7.1 List of Companies Profiled
Table 7.2 Arcturus Therapeutics: Company Overview
Table 7.3 Technology Profile: LUNAR®
Table 7.4 Arcturus Therapeutics: Recent Developments and Future Outlook
Table 7.5 Bio-Path Holdings: Company Overview
Table 7.6 Technology Profile: DNAbilize®
Table 7.7 Bio-Path: Recent Developments and Future Outlook
Table 7.8 CureVac: Company Overview
Table 7.9 Technology Profile: mRNA technology
Table 7.10 CureVac: Recent Developments and Future Outlook
Table 7.11 Entos Pharmaceuticals: Company Overview
Table 7.12 Technology Profile: Fusogenix
Table 7.13 Entos Pharmaceuticals: Recent Developments and Future Outlook
Table 7.14 eTheRNA immunotherapies: Company Overview
Table 7.15 Technology Profile: TriMix technology
Table 7.16 eTheRNA immunotherapies: Recent Developments and Future Outlook
Table 7.17 Matinas Biopharma: Company Overview
Table 7.18 Technology Profile: LNC Platform
Table 7.19 Matinas Biopharma: Recent Developments and Future Outlook
Table 7.20 MDimune: Company Overview
Table 7.21 Technology Profile: BioDrone
Table 7.22 MDimune: Recent Developments and Future Outlook
Table 7.23 PCI Biotech: Company Overview
Table 7.24 Technology Profile: Photochemical internalisation
Table 7.25 PCI Biotech: Recent Developments and Future Outlook
Table 8.1 Patent Analysis: Top Sections
Table 8.2 Patent Analysis: Top Symbols
Table 8.3 Patent Analysis: Top Codes
Table 8.4 Patent Portfolio: Summary of Benchmarking Analysis
Table 8.5 Patent Analysis: Categorization Based on Weighted Valuation Score
Table 8.6 Patent Analysis: List of Relatively Higher Value Patents
Table 9.1 Non-Viral Intracellular Drug Delivery Technologies: Partnerships and Collaborations, 2015-2022
Table 13.1 Biond Biologics: Company Snapshot
Table 13.2 Carmine Therapeutics: Company Snapshot
Table 13.3 Eyevensys: Company Snapshot
Table 13.4 Generation Bio: Company Snapshot
Table 13.5 PCI Biotech: Company Snapshot
Table 13.6 SRI International: Company Snapshot
Table 14.1 Non-Viral Intracellular Drug Delivery Technologies: Distribution by Type of Molecule Delivered
Table 14.2 Non-Viral Intracellular Drug Delivery Technologies: Distribution by Type of Biologic Delivered
Table 14.3 Non-Viral Intracellular Drug Delivery Technologies: Distribution by Type of Interaction
Table 14.4 Non-Viral Intracellular Drug Delivery Technology Providers: Most Active Player Based on Therapeutic Portfolio
Table 14.5 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Year of Establishment
Table 14.6 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Company Size
Table 14.7 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Type of Company
Table 14.8 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Location of Headquarters (By Region)
Table 14.9 Key Insights: Distribution by Type of Technology
Table 14.10 Key Insights: Distribution by Company Size and Type of Molecule Delivered
Table 14.11 Key Insights: Distribution by Location of Headquarters (Region-wise) and Type of Service Provider
Table 14.12 Key Insights: Distribution by Company Size and Location of Headquarters
Table 14.13 Company Competitiveness Analysis: Benchmarking of Service Strength
Table 14.14 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Table 14.15 Company Competitiveness Analysis: Very Small Companies
Table 14.16 Company Competitiveness Analysis: Small Companies
Table 14.17 Company Competitiveness Analysis: Mid-Sized Companies
Table 14.18 Company Competitiveness Analysis: Large and Very Large Companies
Table 14.19 Intracellular Drug Delivery Technologies: Patent Analysis
Table 14.20 Patent Analysis: Distribution by Type of Patent
Table 14.21 Patent Analysis: Distribution by Publication Year
Table 14.22 Patent Analysis: Distribution by Application Year
Table 14.23 Patent Analysis: Distribution by Cumulative Number of Granted Patents
Table 14.24 Patent Analysis: Distribution by Cumulative Number of Patent Applications
Table 14.25 Patent Analysis: Distribution by Issuing Authority
Table 14.26 Patent Analysis: Distribution by Type of Player
Table 14.27 Leading Players: Analysis by Number of Patents
Table 14.28 Leading Inventors: Analysis by Number of Patents
Table 14.29 Patent Analysis: Distribution by CPC Symbols
Table 14.30 Intracellular Drug Delivery Technologies: Patent Benchmarking Analysis
Table 14.31 Intracellular Drug Delivery Technologies: Patent Valuation Analysis
Table 14.32 Partnerships and Collaborations: Cumulative Year-wise Trend of Partnerships, 2015-2022
Table 14.33 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.34 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership, 2015-2022
Table 14.35 Partnerships and Collaborations: Distribution by Purpose of Partnership
Table 14.36 Partnerships and Collaborations: Distribution by Type of Molecule Delivered
Table 14.37 Partnerships and Collaborations: Distribution by Biologic Delivered
Table 14.38 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 14.39 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Payment Model Employed, 2015-2022
Table 14.40 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner 2015-2022
Table 14.41 Most Active Players: Distribution by Purpose of Partnership and Type of Company
Table 14.42 Most Active Players: Distribution by Number of Partnerships
Table 14.43 Most Popular Technologies: Distribution by Region
Table 14.44 Partnerships and Collaborations: Distribution by Year of Partnership, Type of Payment Model Employed and Amount Raised (USD million)
Table 14.45 Partnerships and Collaborations: Local and International Agreements
Table 14.46 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 14.47 Global Non-Viral Intracellular Drug Delivery Technologies Market, 2022-2035 Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.48 Global Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Type of Payment Model Employed, 2022 and 2035
Table 14.49 Global Non-Viral Intracellular Drug Delivery Technologies Market for Upfront Payments, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.50 Global Non-Viral Intracellular Drug Delivery Technologies Market for Milestone Payments, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.51 Global Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Type of Molecule Delivered, 2022 and 2035
Table 14.52 Global Non-Viral Intracellular Drug Delivery Technologies Market for Small Molecule, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.53 Global Non-Viral Intracellular Drug Delivery Technologies Market for Biologics, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.54 Global Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Type of Biologic Delivered, 2022 and 2035
Table 14.55 Global Non-Viral Intracellular Drug Delivery Technologies Market for Antibodies, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.56 Global Non-Viral Intracellular Drug Delivery Technologies Market for DNA, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.57 Global Non-Viral Intracellular Drug Delivery Technologies Market for Protein / Peptide, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.58 Global Non-Viral Intracellular Drug Delivery Technologies Market for RNA, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.59 Global Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Type of Technology, 2022 and 2035
Table 14.60 Global Non-Viral Intracellular Drug Delivery Technologies Market for Cell Penetrating Peptide, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.61 Global Non-Viral Intracellular Drug Delivery Technologies Market for Extracellular Vesicles, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.62 Global Non-Viral Intracellular Drug Delivery Technologies Market for Nanoparticle, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.63 Global Non-Viral Intracellular Drug Delivery Technologies Market for Oligonucleotide, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.64 Global Non-Viral Intracellular Drug Delivery Technologies Market for Polymer, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.65 Global Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Therapeutic Area, 2022 and 2035
Table 14.66 Global Non-Viral Intracellular Drug Delivery Technologies Market for Genetic Disorders, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.67 Global Non-Viral Intracellular Drug Delivery Technologies Market for Hepatic Disorders, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.68 Global Non-Viral Intracellular Drug Delivery Technologies Market for Infectious Diseases, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.69 Global Non-Viral Intracellular Drug Delivery Technologies Market for Neurological Disorders, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.70 Global Non-Viral Intracellular Drug Delivery Technologies Market for Oncological Disorders, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.71 Global Non-Viral Intracellular Drug Delivery Technologies Market for Others, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.72 Global Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Geography, 2022 and 2035
Table 14.73 Non-Viral Intracellular Drug Delivery Technologies Market in North America, 2022 and 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.74 Non-Viral Intracellular Drug Delivery Technologies Market in Europe, 2022 and 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.75 Non-Viral Intracellular Drug Delivery Technologies Market in Asia, 2022 and 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.76 Non-Viral Intracellular Drug Delivery Technologies Market in Latin America, 2022 and 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.77 Non-Viral Intracellular Drug Delivery Technologies Market in Middle East and North Africa, 2022 and 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.78 Non-Viral Intracellular Drug Delivery Technologies Market in Rest of the World, 2022 and 2035, Conservative, Base and Optimistic Scenarios (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. 20Med Therapeutics
  2. Abcam
  3. Acuitas Therapeutics
  4. Acceleron Pharma
  5. Adocia
  6. AgonOx
  7. Alcobra (Acquired by Arcturus Therapeutics)
  8. Aldevron
  9. Alexion Pharmaceuticals
  10. Almirall
  11. Alnylam Pharmaceuticals
  12. AM Chemicals
  13. Amgen
  14. Anjarium Biosciences
  15. Aqdot 
  16. Aquarius Biotechnologies
  17. Arcturus Therapeutics
  18. Arrowhead Pharmaceuticals
  19. Aruna Bio
  20. Ascendis Pharma
  21. Astellas Innovation Management (A subsidiary of Astellas Pharma)
  22. Astellas Pharma
  23. AstraZeneca
  24. Avectas
  25. Avellino Lab
  26. Avicenna Oncology
  27. Avidity Biosciences
  28. Baseceuticals (Division of Creative Biogene)
  29. Basilard BioTech
  30. Bavarian Nordic
  31. BeiGene
  32. Bicycle Therapeutics
  33. BioCellChallenge
  34. BioGene
  35. BioMarin Pharmaceuticals
  36. BioMoti
  37. Biond Biologics
  38. Bioneer
  39. BioNet-Asia
  40. BioNTech
  41. Biopact Ventures
  42. Bio- Path Holdings
  43. Bio-Techne
  44. BOC Sciences
  45. Carisma Therapeutics
  46. Carmine Therapeutics
  47. Catamaran Bio
  48. CCRM
  49. Celanese
  50. Cell and Gene Therapy Catapult
  51. Cellectar Biosciences
  52. Cellics Therapeutics
  53. Center for Cancer Immune Therapy (Herlev Hospital)
  54. Centre for Process Innovation
  55. CEPI
  56. Chimeron Bio
  57. Code Biotherapeutics
  58. Codiak BioSciences
  59. CQDM
  60. Cristal Therapeutics
  61. Croda
  62. Crucell (A subsidiary of Johnson & Johnson)
  63. CureVac
  64. Cybrexa Therapeutics
  65. CyGenica
  66. Cytiva
  67. DCprime (Acquired by Van Herk Investments)
  68. Deloitte
  69. Dicerna Pharmaceuticals
  70. Duke-NUS Medical School
  71. Editas Medicine
  72. Effimune
  73. Eisai
  74. Elasmogen
  75. Eli Lilly
  76. Emisphere Technologies
  77. enGene
  78. EnGeneIC
  79. Entos Pharmaceuticals
  80. Entrada Therapeutics
  81. EpiVax
  82. eTheRNA
  83. Ethris
  84. Evercyte
  85. Evox Therapeutics
  86. ExonanoRNA
  87. Eyevensys
  88. Feldan Therapeutics
  89. Frame Therapeutics (Acquired by CureVac)
  90. FUJIFILM Diosynth Biotechnologies
  91. GC Biopharma
  92. GenEdit
  93. Generation Bio 
  94. GeneTech
  95. Genevant
  96. Genmab 
  97. Genprex
  98. Genzyme
  99. George Mason University
  100. Geprex
  101. Glycostem Therapeutics
  102. GreenCross LabCell
  103. Gritstone bio
  104. GSK
  105. Guggenheim Securities
  106. Gustave Roussy
  107. Hansoh Pharma
  108. Helmholtz Zentrum München
  109. HK Innoen
  110. Hopewell Therapeutics
  111. ILIAS Biologics
  112. Image Analysis Group (IAG)
  113. ImmunityBio
  114. ImmunoForge
  115. IMV
  116. In-Cell-Art
  117. Incisive Genetics
  118. Inha University
  119. InnoCore Pharmaceuticals
  120. InnoRNA
  121. Innovent Biologics
  122. Institut Pasteur
  123. Intergalactic Therapeutics
  124. Intract Pharma
  125. Ionis Pharmaceuticals
  126. Iovance Biotherapeutics
  127. iTeos Therapeutics
  128. Janssen Pharmaceuticals
  129. Jazz Pharmaceuticals
  130. JW Pharmaceutical
  131. Kinos Medical
  132. Kite Pharma (A Gilead Company)
  133. Kodikaz Therapeutics
  134. Kyungpook National University
  135. Larimar Therapeutics
  136. Leeyeon Pharmaceutical
  137. LegoChem Biosciences
  138. LGC
  139. Libera Bio
  140. Lions Eye Institute
  141. Luminary Therapeutics
  142. Mallinckrodt Pharmaceuticals
  143. Matinas BioPharma
  144. McKinsey & Company
  145. MDimune
  146. Medicines Patent Pool
  147. Medigene
  148. MedinCell 
  149. Mediphage Bioceuticals
  150. Mekonos
  151. Merck
  152. Millendo Therapeutics
  153. MirImmune
  154. University of Münster
  155. Myeloid Therapeutics
  156. Mymetics
  157. myNEO
  158. Myosana Therapeutics
  159. Myotonic Dystrophy Foundation
  160. N4 Pharma
  161. NanoDe Therapeutics
  162. Nanomerics
  163. National Cancer Institute (NCI)
  164. National Institute of Allergy and Infectious Diseases
  165. National Institutes of Health
  166. National University of Singapore
  167. Nature Technology Corporation
  168. Navigo Proteins
  169. Neochromosome
  170. NeoCura
  171. Neurimmune
  172. Novartis
  173. Novo Nordisk
  174. Novochizol
  175. Oisin Biotechnologies
  176. OliX Pharmaceuticals
  177. Onconova Therapeutics
  178. ONK Therapeutics
  179. Orion Corporation
  180. Osong Advanced Medical Foundation
  181. Ovensa
  182. Pacira BioSciences
  183. PAGS
  184. Pantherna Therapeutics
  185. PCI Biotech
  186. PeptiDream
  187. Pfizer
  188. Phio Pharmaceutials
  189. pHion Therapeutics
  190. PLx Pharma
  191. Poseida Therapeutics
  192. Precigen
  193. Precision NanoSystems
  194. PROVIREX
  195. PYC Therapeutics
  196. R&D Systems (A Bio-Techne brand)
  197. Ragon Institute
  198. Reach Regulation
  199. Regeneron
  200. ReNeuron
  201. Rexahn Pharmaceuticals
  202. Reyon Pharmaceutical
  203. RNAimmune
  204. Roche
  205. RXi Pharmaceuticals
  206. SalioGen Therapeutics
  207. Samsung Seoul Hospital
  208. Sandoz (A Novartis Division)
  209. Sanofi-Aventis Deutschland
  210. Sapreme Technologies
  211. Sarepta Therapeutics
  212. Seoul National University
  213. Seqirus
  214. Shire
  215. Silence Therapeutics
  216. Sirnaomics
  217. SiSaf
  218. Sixfold Bioscience
  219. SmartPharm Therapeutics
  220. SomaServe
  221. SRI International
  222. Starpharma
  223. Synthetic Genomics
  224. Taiba Healthcare
  225. Takeda Pharmaceuticals 
  226. Tetra Bio-Pharma
  227. The University of Texas MD Anderson Cancer Center
  228. Théa Open Innovation
  229. Thomas Jefferson University
  230. Tianjin Chase Sun Pharmaceutical
  231. Tonghua Dongbao
  232. Translate Bio
  233. Tyris Tx
  234. Ultimovacs
  235. Ultragenyx Pharmaceutical
  236. University of Aberdeen
  237. University of California (The Simon Lab)
  238. University of L'Aquila
  239. University of Oxford
  240. University of Pittsburgh
  241. University of Texas Southwestern Medical Center
  242. Verve Therapeutics
  243. Vesigen Therapeutics
  244. ViiV Healthcare
  245. Vingroup 
  246. Vir Biotechnology 
  247. Vrije Universiteit Brussel (VUB) 
  248. Vycellix
  249. Wisconsin Alumni Research Foundation (WARF)
  250. YiPSCELL
  251. Yuhan
  252. Zhejiang Haichang Biotechnology    

Source 1: https://www.nature.com/articles/s41598-019-55091-0
Source 2: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470022/

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.